Stockreport

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

Invivyd, Inc.  (IVVD) 
PDF Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people [Read more]